These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 7191289)
1. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin. Bhargava AS; Heinick J; Günzel P Arzneimittelforschung; 1980; 30(7):1071-4. PubMed ID: 7191289 [TBL] [Abstract][Full Text] [Related]
2. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa. Tran TH; Bondeli C; Marbet GA; Duckert F Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997 [TBL] [Abstract][Full Text] [Related]
3. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats. Diness V; Ostergaard PB Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964 [TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments. Racanelli A; Fareed J; Walenga JM; Coyne E Semin Thromb Hemost; 1985 Apr; 11(2):176-89. PubMed ID: 4035365 [No Abstract] [Full Text] [Related]
5. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826 [TBL] [Abstract][Full Text] [Related]
6. The monitoring of heparin administration by screening tests in experimental dogs. Mischke R; Jacobs C Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088 [TBL] [Abstract][Full Text] [Related]
7. GAGs-potentiated inhibition of thrombin, factor Xa and plasmin in plasma and in a purified system containing antithrombin III - correlation with total charge density. Cofrancesco E; Vigo A; Pogliani EM Thromb Haemost; 1981 Dec; 46(4):749-51. PubMed ID: 6460339 [TBL] [Abstract][Full Text] [Related]
8. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291 [TBL] [Abstract][Full Text] [Related]
9. Characterization of a new potent heparin. 7th communication: A comparative study of a new potent heparin in human after i.v. application. Bhargava AS; Wendt H; Günzel P Arzneimittelforschung; 1981; 31(2):386-8. PubMed ID: 7194658 [TBL] [Abstract][Full Text] [Related]
10. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Hérault JP; Bernat A; Gaich C; Herbert M Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma. Bhargava AS; Heinick J; Schöbel C; Günzel P Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280 [TBL] [Abstract][Full Text] [Related]
12. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169). Walenga JM; Fareed J; Hoppensteadt DA Semin Thromb Hemost; 1985 Jan; 11(1):17-25. PubMed ID: 3883497 [TBL] [Abstract][Full Text] [Related]
13. An investigation of the functional role of the carboxylic groups of heparin. Affinity for antithrombin III and anti-Xa activity of selectively carboxyl esterified heparin. Mardiguian J; Trillou M Semin Thromb Hemost; 1985 Jan; 11(1):34-6. PubMed ID: 3975640 [No Abstract] [Full Text] [Related]
14. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence. Bohner J; von Pape KW; Blaurock M Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789 [TBL] [Abstract][Full Text] [Related]
15. Anticoagulant properties of extracellular slime substance produced by Staphylococcus epidermidis. Bykowska K; Ludwicka A; Wegrzynowicz Z; Lopaciuk S; Kopeć M Thromb Haemost; 1985 Dec; 54(4):853-6. PubMed ID: 4089818 [TBL] [Abstract][Full Text] [Related]
16. Heparin assay: a comparison between titrimetric and amidolytic methods. Nenci GG; Berrettini M; Agnelli G; Parise P Boll Soc Ital Biol Sper; 1980 Mar; 56(5):519-25. PubMed ID: 7387799 [TBL] [Abstract][Full Text] [Related]
17. Effect of heparin on the neutralization of factor Xa and thrombin by the plasma alpha-2-globulin inhibitor. Yin ET Thromb Diath Haemorrh; 1975 Feb; 33(1):43-50. PubMed ID: 47195 [No Abstract] [Full Text] [Related]
18. Anticoagulant activity of artificial biomedical materials with co-immobilized antithrombin III and heparin. Miura Y; Aoyagi S; Ikeda F; Miyamoto K Biochimie; 1980; 62(8-9):595-601. PubMed ID: 7417594 [TBL] [Abstract][Full Text] [Related]
19. Characterization of a new potent heparin. 6th communication: The comparison of the anticoagulant effect of the sodium and calcium salts of a new potent heparin after s.c. injection in beagle dogs. Bhargava AS; Schöbel C; Günzel P Arzneimittelforschung; 1981; 31(1):79-82. PubMed ID: 7194097 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacology of heparin]. Hoffmann A; Markwardt F Z Gesamte Inn Med; 1979 Jan; 34(1):3-8. PubMed ID: 373277 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]